Antibody generation and engineering services for allergen and mycotoxin lateral flow diagnostics
Specialized antibody discovery, engineering, and supply services optimized for lateral flow assay development. Leverages proprietary platforms including CDRx humanization and AI-driven sequence generation to produce high-quality, developable antibodies against allergens and mycotoxins, with full cell line development capabilities.
Overview
Fusion Antibodies offers end-to-end antibody generation and engineering services specifically tailored for allergen and mycotoxin detection in lateral flow diagnostic formats. With over 20 years of experience in antibody discovery, engineering, and supply, the company provides expertise in configuring antibodies for optimal performance in lateral flow assays. The service addresses the critical challenge of ensuring antibody suitability and behavior compatibility when transitioning from other diagnostic formats such as ELISA into lateral flow platforms. Clients benefit from a streamlined process that delivers well-characterized, high-performing antibodies ready for diagnostic application.
Technical specifications
Key capabilities:
- Antigen design and expression for immunization within discovery platforms generating hybridoma and B-cell sequences
- CDRx humanization platform for converting murine antibodies into humanized variants
- AI-driven sequence generation for computational antibody design
- Developability engineering including stability optimization and sequence refinement for manufacturability
- Transient expression in CHO cells at volumes up to 35L for purification and characterization
- Binding analysis via Octet, kinetics, and surface plasmon resonance (SPR)
- Stable cell line development (CLD) capable of achieving greater than 8g/L expression yields in under 20 weeks
- Full cGMP-ready cell line generation for manufacturing scale-up
Process timeline:
- Initial antigen design and immunization (if required): variable timeline
- Engineering to shipment: 12 weeks for supplied sequences
- Cell line development milestone: targeting antibody supply cost below $100/mg
Technology readiness level
The antibody engineering platforms have been validated through more than 275 successful humanization projects, with over 8 molecules currently progressing through clinical trials. The technology is commercially deployed and actively serving pharmaceutical, biotech, and life science clients. Mammalian protein production and cell line development capabilities are fully operational within the company's facilities. The AI-driven antibody discovery technology represents a recent expansion to maintain competitive advantage in the biotechnology sector. All services are available immediately for client engagement, with established workflows supporting both therapeutic and diagnostic antibody development programs.
About Fusion Antibodies PLC
Fusion Antibodies PLC is a Northern Ireland-based contract research organization (CRO) that provides specialized services for the discovery, engineering, and supply of therapeutic and diagnostic antibodies. The company operates as an extension of its clients' teams, supporting projects from initial antigen design through to cell line development. Its proprietary technology platforms—such as CDRx for antibody humanization and RAMP for affinity maturation—are designed to optimize the performance, manufacturability, and developability of antibodies at a molecular level. The company also offers mammalian protein production services and has expanded into artificial intelligence-driven antibody discovery technologies to maintain a competitive edge in the biotechnology sector.
By helping clients navigate the complex pre-clinical stages of development, Fusion Antibodies enables pharmaceutical, biotech, and life science companies to streamline the progression of clinical candidates. Their work is essential for developing high-quality, high-expressing cell lines that meet cGMP standards, ultimately aiming to reduce the costs and timelines associated with drug development. The firm, founded in 2001 and publicly traded on the London Stock Exchange, works with a diverse range of collaborators to move projects into clinical trials, providing expertise that spans human and veterinary therapeutics as well as diagnostic applications.
Inquire about this partnering listing
Available for
Industry applications
delivered to your inbox.